Incretin-Based Therapies: Viewpoints on the way to consensus by Nauck, Michael. A. et al.
Incretin-Based Therapies
Viewpoints on the way to consensus
MICHAEL.A .N AUCK, MD
1
TINA VILSBØLL, MD
2
BAPTIST GALLWITZ, MD
3
ALAN GARBER, MD
4
STEN MADSBAD, MD
5
INTRODUCTION (BY
M.A.N.) — Incretinmimeticsandin-
hibitors of the protease dipeptidyl pep-
tidase (DPP)-4 are new classes of
antidiabetic agents ﬁrst introduced in
the years 2005 (exenatide) and 2007
(sitagliptin), respectively. Both use the
antidiabetic properties of the incretin
hormone, glucagon-like peptide (GLP)-1
(1). This gut-derived peptide hormone
not only augments glucose-induced insu-
lin secretion (required to fulﬁll the deﬁni-
tion of an incretin hormone), but does so
in a highly glucose-dependent manner
(2), thus preventing GLP-1 alone from
provoking hypoglycemia. Additional
beneﬁcial effects of GLP-1 on endocrine
pancreatic islets are that it 1) supports the
synthesis of proinsulin to replenish insu-
lin stores in -cells; 2) reduces the rate of
-cellapoptosiswhenisletsareincubated
in a toxic environment (glucotoxicity, li-
potoxicity, cytotoxic cytokines); and 3)
promotes differentiation of precursor
cells with the ability to develop into
-cells and proliferation of -cell lines,
and in whole animals (rodent studies),
this leads to an increased -cell mass
withinafewdaysorweeks(1,3).Further-
more, GLP-1 can lower glucagon concen-
trations, i.e., induce -cells to respond
again to the inhibitory action of hypergly-
cemia, while leaving the counterregula-
tory glucagon responses undisturbed, as
in the case of hypoglycemia (2,4). Addi-
tional activities of GLP-1 are the deceler-
ationofgastricemptying(5),whichslows
the entry of nutrients into the circulation
after meals, a reduction in appetite, and
earlier induction of satiety (6), leading to
weight reduction with chronic exposure
(7). Renal effects (promotion of sodium
and water excretion (8), as well as neuro-
(9) and cardioprotective (10) properties of
GLP-1, have also been described. While
GLP-1 is perfectly suitable for lowering,
or even stabilizing, glucose concentra-
tions in short-term experiments, its short
half-life (1–2 min for the intact, biolog-
icallyactiveform)causedbyrapidproteo-
lytic degradation and inactivation
through the ubiquitous enzyme DPP-4
and renal elimination (Fig. 1A) prohibits
long-term use for treatment of a chronic
condition, such as type 2 diabetes (1).
For this reason, incretin mimetics
(e.g., exenatide and liraglutide) with con-
siderably longer half-lives have been de-
veloped.Exenatideisasyntheticformofa
natural peptide found in the saliva of He-
loderma suspectum (11). Through its
amino acid sequence homology with
GLP-1, it is able to interact with GLP-1
receptors and to mimic all aspects of the
antidiabetic activity of GLP-1 (12). Ex-
enatide has a half-life of 3 h and has
been approved for administration (twice-
daily injections) to type 2 diabetic pa-
tients inadequately controlled by oral
antidiabetic agents. Recently developed
liraglutide,synthesizedbyattachingafree
fatty acid to a slightly modiﬁed GLP-1
molecule, is characterized by a half-life of
12–14 h (suitable for once-daily adminis-
tration) (13,14). In 2008, results of phase
3 studies were presented, thus facilitating
assessment of the potential of this novel
agent in the treatment of patients with
type 2 diabetes. A common feature of all
incretinmimeticsisthattheyarepeptides
and need to be administered by subcuta-
neousinjection.Theybindtoandactivate
the GLP-1 receptor and display the full
array of biological (antidiabetic) activity
known for/characteristic of GLP-1.
Within the group of incretin mimetics,
differencesareseenwithrespecttoamino
acid homology in comparison to native
human GLP-1, and in pharmacokinetic
characteristics, such as elimination of
half-lives, and so forth. Novel attempts
have aimed at developing compounds, or
preparations, with a longer duration of
action, and less frequent administration
(e.g., once-weekly) (15).
Another method of exploiting the an-
tidiabetic potential of GLP-1 is by inhib-
iting its proteolytic degradation and
inactivation through the action of DPP-4.
Several agents have been identiﬁed that
are able to inhibit DPP-4 activity (in se-
rum) by 85% and preserve GLP-1 se-
creted from endogenous sources (mainly
in response to meal ingestion) in its intact
biologically active forms (GLP-1 [7-36
amide] or GLP-1 [7-37]), thus leading to
doubled or tripled integrated incremental
responses (16,17). This goes along with
stimulation of insulin secretion (relative
to the glycemic rise accompanying nutri-
ent ingestion), suppression of the meal-
related glucagon response, and a reduction
in fasting and postprandial glucose con-
centrations (16), which translate into a
lowerA1Cvalueinthelongterm(18,19).
Sitagliptin and vildagliptin (not yet in the
U.S.) have been approved as novel oral
antidiabetic agents. Alogliptin and saxa-
gliptin are additional agents having un-
dergone clinical studies.
As expected, when two novel classes
of antidiabetic agents, both related to the
gut endocrine (“incretin”) system, are in-
troduced into the market within a short
period of time, the properties of the types
and agents need to be discussed to deter-
mine their clinical value and to deﬁne
how they should best be used in clinical
practice(selectionofpatients,initiationof
treatment, co-medication, and so forth).
The present viewpoints focus on several
crucial questions that characterize state-
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therapy today.
DIFFERENT APPROACHES TO
DIABETES THERAPY— Although
GLP-1 receptor agonists (“incretin mi-
metics”) and DPP-4 inhibitors (“incretin
enhancers”) are based on antidiabetic
properties of insulinotropic gut hor-
mones(“incretins”),theyrepresentdiffer-
ent approaches to the therapy of type 2
diabetes.
What are the similarities? (by T.V.)
Treatment with GLP-1 receptor agonists
(“incretin mimetics”) and DPP-4 inhibi-
tors (“incretin enhancers”) are based on
antidiabetic properties of insulinotropic
gut hormones (“incretins”). Although
they represent different approaches to
therapy in patients with type 2 diabetes,
there are notable similarities (Table 1).
First, both therapy approaches en-
gender signiﬁcant and clinically relevant
improvement in glycemic control regard-
ing fasting plasma glucose, postprandial
glucose, and A1C (1,20).
Both treatment modalities beneﬁt
from the glucose-dependent effect of
GLP-1 on insulin secretion and glucagon
inhibition, whereby improvements in
glucose control can be achieved with
minimal risk of hypoglycemia when
combined with metformin or thiazo-
lidinedione (TZD) (1). However, when
GLP-1 is combined with sulfonylureas,
the risk of hypoglycemia appears to be
similartothatofsulfonylureasalone(21).
Studiesindicatethatbothincretinmi-
metics and enhancers target the most ex-
citing aspects of the incretin-based
therapies.Itispossiblethatbecauseofthe
protectiveandperhapstropiceffectofmi-
metics and enhancers on the pancreatic
-cells, the progression of disease that in-
evitably seems to accompany conven-
tionaltreatmentmaychange.Todate,this
has not been established in clinical trials,
but animal studies with mimetics and en-
hancers have shown that -cell prolifera-
tion and cytoprotection is seen with both
(1,3).
What are the differences? (by B.G.)
Incretin mimetics as peptides have to be
injected subcutaneously. They raise the
concentrations of GLP-1 receptor ago-
nists to pharmacologically high levels,
leading to concentrations 6- to 10-fold
thatofthephysiologicalonesfoundinthe
postprandial state (14,15,22). The exoge-
nous administration of GLP-1 receptor
Figure 1—Schematic diagram explaining the physiological (postprandial) secretion of GLP-1 from
thegut,itsbindingtoGLP-1receptors(e.g.,onpancreaticendocrine-cells),anditsdegradationbythe
ubiquitous protease DPP-4 as well as its rapid renal elimination (A). Incretin mimetics are peptide
GLP-1receptoragonistsmoreorlessstructurallysimilartoGLP-1,whichbindandactivatetheGLP-1
receptor, but are not degraded by DPP-4 and have much slower elimination pharmacokinetics (B).
DPP-4 inhibitors prevent the degradation/inactivation of the biologically active form of GLP-1 and,
thereby, augment the biological activity of GLP-1 released from endogenous sources (C).
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results in constantly high plasma con-
centrations and consecutively in a
continuous and exclusive stimulation of
the GLP-1 receptor. This stimulatory
route with high GLP-1 agonist plasma
concentration is thought to mediate the
predominantly endocrine and systemic
effects of GLP-1 (1,23). Apart from the
insulinotropic and glucagonostatic ac-
tions, the actions of incretin mimetics in-
cludetheslowingofgastricemptyingthat
may result in sensations of fullness, or
nauseaatinitiationoftherapy,aswellasa
stimulation of satiety in the central ner-
vous system (5,6). Currently, it is not
known to what exact extent both effects
contribute to weight loss and reduced ap-
petite. In clinical studies, patients receiv-
ing incretin mimetics had body weight
loss irrespective of nausea as an adverse
event, favoring a regulatory action on the
central nervous system (24,25), whereas
patientstreatedwithDPP-4inhibitorsdid
not substantially change their weight (1).
The formation of anti-exentide anti-
bodies has been observed in 45% of pa-
tients on exenatide therapy (20). High
antibody titers may be associated with
some loss of efﬁcacy of exenatide (15).
With liraglutide, the incidence of anti-
body formation is lower (5–8%) (26).
DPP-4 inhibitors can be ingested
orally and produce a longer biological
half-life of peptides that are substrates for
this enzyme, like GLP-1 (1,16,17).
Since DPP-4 is found in the endothe-
lium of the submucosal capillaries in the
smallintestine,effectsofDPP-4inhibitors
are also thought to be mediated locally,
throughGLP-1receptorsonvagalafferent
ﬁbers, in addition to being a true endo-
crine signal (27) (Table 2).
Differences between incretin mimet-
ics and DPP-4 inhibitors also concern the
respective proﬁle of adverse events (20):
gastrointestinal side effects are most typi-
cal for incretin mimetics (1). Some cases
of pancreatitis have been reported, but it
isnotclear,whethertheyhaveoccurredat
a higher rate than expected for an obese
type 2 diabetic population. A somewhat
higher rate of nasopharyngitis was re-
ported in patients treated with DPP-4 in-
hibitors, but this no longer is supported
by a recent report on sitagliptin adverse
events (28). Occasional elevations in liver
enzymes have been reported with vilda-
gliptin, and skin lesions were described
with sitagliptin treatment in rare cases.
Table 2 summarizes the differences be-
tween incretin mimetics and DPP-4
inhibitors.
ADVANTAGES OF INCRETIN
MIMETICS AND DPP-4
INHIBITORS— Based on currently
availableinformation(phase3studiesde-
signed for drug approval), incretin mi-
metics and DPP-4 inhibitors have
advantages over other antidiabetic drugs.
What are the obvious beneﬁts for
the patients? (by A.G.)
Novel effects have been found with incre-
tin-based therapies, such as GLP-1 recep-
tor agonists (exenatide; liraglutide in
phase 3 trials) and DPP-4 inhibitors (sita-
gliptin; vildagliptin), which are beneﬁcial
to patients and are not found with other
antidiabetic treatments. Perhaps the most
signiﬁcant of these is the glucose-
dependent nature of their insulinotropic
effects, which means that incretin-based
therapies mimic closely the physiologic
insulin proﬁle and are associated with
very low rates of hypoglycemia. In addi-
tion to this key property, and also of ma-
jor signiﬁcance, incretin-based therapies
do not cause weight gain. In fact, GLP-1
receptor agonists provoke signiﬁcant
weight loss, which is especially important
when considered against the weight gain
associated with, e.g., sulfonylureas,
TZDs, and insulin (29–32). DPP-4 inhib-
itors at least are weight neutral (1,20).
Additional novel features include the
positive effect of some incretin-based
therapies on the -cell. GLP-1 receptor
agonists improve some parameters of
-cell function during treatment (33,34),
while a lasting effect after an appropriate
washout period has not been demon-
strated after 1 year of treatment with ex-
enatide (35). Finally, one may expect a
Table 1—Similarities of incretin-based therapies
Properties/action Incretin mimetics DPP-4 inhibitors
Glucose-dependent insulin secretion Yes Yes
Glucose-dependent glucagonostatic effect Yes Yes
Effect on fasting plasma glucose (reduction) By 1.4–3.4 mmol/l By 1.0–1.4 mmol/l
Effect on postprandial glucose Yes Yes (but weaker)
Effect on A1C (reduction) By 0.8–1.8% By 0.5–1.1%
Effect on (pro)insulin biosynthesis Yes Yes (weaker?)
Improved in vivo -cell function (in humans) Yes* Yes*
Beneﬁcial cardiovascular effects Probable Not proven
*As determined while patients received treatment (lasting effects need to be proven after washing out
treatment).
Table 2—Differences of incretin-based therapies
Properties/action Incretin mimetics DPP-4 inhibitors
Administration Subcutaneous Oral
GLP-1 levels (or equivalent) Pharmacological (six- to tenfold) Physiological (two- to threefold)
Main mechanism of GLP-1
receptor stimulation
Interaction with receptors on target organs/cells Interaction with receptors on afferent nerves
(autonomous nervous system)
Other mediators No GIP, PACAP, others (questionable)
Effects on gastric emptying Yes No (hardly)
Effects on appetite Reduced Hardly inﬂuenced
Effects on body weight Weight loss Weight neutrality
Adverse events Nausea, vomiting, antibodies (exenatide,
relevance?), pancreatitis (causal relation?)
Upper respiratory tract infections, elevations in
liver enzymes (vildagliptin), skin reactions
(sitagliptin)
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continuing loss in -cell function (36),
from such treatment. This, however,
needs to be demonstrated. A hint in this
direction may be read from the absolutely
constant fasting plasma glucose and A1C
concentration during liraglutide treat-
ment in previously drug-naïve type 2 di-
abetic patients for a full year (26). Most
likely, longer treatment will be required
to support ﬁrm conclusions on this issue.
Regarding DPP-4 inhibitors, only prelim-
inary data regarding -cell function and
nonprogression is available (37,38).
Mechanistic studies have suggested
cardio-protective activity of GLP-1 (39).
SimilareffectsmaybepresentwithGLP-1
receptor agonists. Clinical trials have
shown effects of exenatide and liraglutide
on surrogate cardiovascular parameters
such as systolic blood pressure (31,33),
triglycerides, and brain natriuretic pep-
tide (24). Long-term studies proving car-
diovascular beneﬁt are necessary for both
incretin mimetics and DPP-4 inhibitors.
Besides their positive therapeutic ef-
fects, incretin-based therapies offer ad-
vantages over traditional oral agents and
insulin, in terms of both convenience and
reduced side effects, especially with re-
gard to the expected frequency of hypo-
glycemia and weight gain. Based on these
important properties, GLP-1 receptor
agonists have been mentioned in recent
treatment algorithms for the treatment of
type2diabetes,however,aslessvalidated
therapy (40,41).
What information is currently
lacking but would be needed for an
unequivocal recommendation? (by
S.M.)
Choosingantihyperglycemicagentsisde-
termined by their efﬁcacy in lowering
blood glucose and their extraglycemic ef-
fects (including effects on cardiovascular
disease and microangiopathy), adverse
events, and costs. GLP-1 receptor ago-
nists and DPP-4 inhibitors are relatively
novel classes of drugs. To unequivocally
recommend these two new drug types,
the following information is lacking and
should be provided: 1) Current data on
the durability of glycemic control are in-
sufﬁcient, 2) the durability and magni-
tude of weight regulation are currently
unknown, 3) neither GLP-1 receptor ago-
nists nor DPP-4 inhibitors have been in-
vestigated in trials of sufﬁcient size and
duration to evaluate their effects on car-
diovascular outcomes, and 4) long-term
trialsonsafetywithprospectivecollection
of adverse events are needed over and
above what has been reported so far.
TheAMIGOstudiesshowedthatafter
30 weeks of exenatide treatment, the re-
duction in A1C was 0.8–1.0% com-
pared with placebo treatment (1). In the
three AMIGO studies, a total of 1,441
type 2 diabetic patients were included,
and during a 3-year follow-up of a sub-
group of participants (n  314), the re-
duction of A1C was stabilized at 1.1%
(33). In a comparison between exenatide
and insulin glargine, or premixed aspart
insulin, the lowering of A1C did not
differ between the groups during 6 and
12 months of treatment. The efﬁcacy of
exenatide in lowering A1C compared
with other oral antidiabetic agents is
unknown.
With the once-daily GLP-1 receptor
agonist liraglutide, which offers a 24-h
proﬁle of action, the placebo-adjusted re-
duction in A1C was 1.7% after 14 weeks
of treatment (24). In the LEAD program
(LiraglutideEffectandActioninDiabetes,
including 6,500 people, of which
4,440participantsreceivedliraglutide),
liraglutide was compared with rosiglita-
zone as an add-on to glimepiride (LEAD
1), with a reduction in A1C of 1.1 and
0.5%infavorofliraglutideafter26weeks
(32). In LEAD 2 (add on to metformin),
the reduction in the liraglutide- and
glimepiride-treated groups did not differ
after 26 weeks follow-up (1.0 vs.
1.0%,respectively)(31).Conversely,in
a 52-week study of drug-naïve patients,
the reduction in A1C was 1.1 and 0.45%,
respectively, for the liraglutide and
glimepiride groups (LEAD 3), indicating
better durability of glycemic control with
liraglutide (26). In LEAD 5, liraglutide
was compared with insulin glargine in
type2diabeticpatients,whohadfailedon
combinationtherapywithmetforminand
sulfonylureas (42). After 26 weeks, A1C
levels were reduced to 1.3 and 1.1% in
favor of liraglutide. Therefore, the reduc-
tion in A1C levels appears to be similar or
greater with the GLP-1 receptor agonist
liraglutide compared with other antidia-
betic drugs.
More than 25 studies have been pub-
lishedonsitagliptinandvildagliptintreat-
ment as add-ons to various antidiabetic
regimens. In a few studies, these DPP-4
inhibitors have been compared with met-
formin, sulfonylurea, rosiglitazone, or
pioglitazone (43). Most studies have been
of short duration (30 weeks). The re-
duction in A1C was 0.6–0.8% com-
pared with placebo during the ﬁrst 6
months of treatment (20,43). In compar-
ison with glipizide, metformin, rosiglita-
zone, or pioglitazone, the reductions in
A1C were similar or slightly less (by
0.2–0.3%) in the DPP-4 inhibitor-
treated patients (20,43).
At present, no robust human data in-
dicate that incretin-based therapy may
protect or restore -cell function or even
mass. Thus, there was no change in -cell
function before start of treatment, or
when tested after 1-year treatment with
exenatidefollowedbya1-monthwashout
of exenatide (35). Regarding DPP-4 in-
hibitors, in a 52-week trial looking at the
efﬁcacy of sitagliptin versus glipizide
added to ongoing metformin therapy, the
maximal efﬁcacy in A1C reduction was
observed at week 24–30, with a gradual
rise in A1C from week 30 to 52, however,
at a slower pace with the DPP-4 inhibitor
(19).Longer-termstudieslastingforupto
2yearswithvildagliptinhavenotresulted
in uniform results regarding the “durabil-
ity” of glucose-lowering effectivity
(37,38). Therefore, any potential long-
term beneﬁts for incretin-based therapy
from preventing deterioration in -cell
function remain to be proven.
A longer durability of glycemic con-
trol may also be expected from persisting
weight loss. The DPP-4 inhibitors are
weight neutral, whereas the GLP-1 recep-
tor agonists induce weight loss (1,20).
The precise durability and magnitude of
weightregulationarecurrentlyunknown.
In the AMIGO and LEAD studies, weight
loss after 14–52 weeks of treatment was
1.5–4 kg compared with placebo treat-
ment (1,20,26,31,32,43). However,
20–25% of patients in the AMIGO
studies and the LEAD program did not
lose weight during treatment with ex-
enatide or liraglutide, respectively. The
reasons are not obvious, but could be ex-
plained by lower bioavailability of the
drugs in some patients. Relatively high
levelsofGLP-1areneededforweightreg-
ulation (44), which also explains the ab-
sent effect on weight loss during
treatment with DPP-4 inhibitors. DPP-4
inhibitors do not have a consistent effect
on lipid proﬁles, and any reduction in
blood pressure is minimal (43).
Type 2 diabetes is associated with a
high risk of cardiovascular disease. Ide-
ally, diabetic drugs should improve mac-
rovascular outcomes and mortality.
Neither GLP-1 receptor agonists nor
DPP-4 inhibitors have been investigated
in trials of sufﬁcient size to evaluate their
effects on cardiovascular end points.
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months) safety data in human subjects
during treatment with GLP-1 receptor
agonists and DPP-4 inhibitors are avail-
able. Regarding adverse events of GLP-1
receptor agonists, the focus has been on
pancreatitis and thyroid C-cell neoplastic
changes. More than 150 cases of pancre-
atitishavebeenreviewedbytheU.S.Food
and Drug Administration post-marketing
during treatment with exenatide, and ﬁve
cases have been diagnosed during the
LEAD program with liraglutide, although
additional cases occurred on, e.g.,
glimepiride as well. However, it is not
clear whether the overall incidence is
higher than expected in an obese type 2
diabetic population. Thyroid C-cell ade-
nomas, which have been observed in ro-
dents,havenotbeenseeninhumans(24).
Recent reports have also linked increased
levels of GLP-1 with the development of
nesidioblastosis and hypoglycemia in a
small number of patients who had under-
gone gastric bypass (45). A reanalysis of
the same pancreatic sections, however,
when compared with appropriate control
pancreases, did not reveal -cell hyper-
plasia as originally suspected (46).
DPP-4,alsoknownasCD26,isfound
asamembraneproteinexpressedinmany
different tissues, including lymphocytes,
and in a circulating soluble form (47);
DPP-4 inhibitors also prolong the action
of a number of growth factors, neuropep-
tides,cytokines,chemokines,andvarious
hormones other than GLP-1 and gastric
inhibitory polypeptide (47). Potential
sideeffectsincludeneurogenicinﬂamma-
tionandallergicreactions(48).Inarecent
Cochrane review of 25 trials with DPP-4
inhibitors, more infections (i.e., urinary
tract infections and nasopharyngitis)
were observed in the groups treated with
sitagliptin or vildagliptin (43). Additional
reported side effects are abdominal pain,
nausea, diarrhea, and arthralgias. Post-
marketing reports include anaphylaxis,
angioedema, and exfoliative skin condi-
tions, including Steven-Johnsons syn-
drome.Basedonarecentmeta-analysisof
12 large-phase IIb and III studies with up
to 2 years’ duration including 6,139 pa-
tientsreceivingeithersitagliptinoracom-
parator agent, the incidence rates of
serious adverse events and discontinua-
tions due to adverse events, however,
were similar in the two groups, indicating
thatsitagliptiniswelltolerated(28).Only
nasopharyngitis occurred more fre-
quently in the sitagliptin group, whereas
the incidence of urinary tract infection
was similar in the groups.
INCRETIN MIMETICS AND
DPP-4 INHIBITORS— Incretin
mimetics and DPP-4 inhibitors will be/
will not be used in the same patient pop-
ulation, i.e., at the same “stage” of type 2
diabetes.
Proﬁle of incretin mimetics and
DPP-4 inhibitors is so similar that
there are no differential indications
(by S.M.)
Given that the GLP-1 receptor agonists
and DPP-4 inhibitors have not yet been
compared head-to-head in any long-
term clinical trial, it is difﬁcult to iden-
tify the patient population most likely
to respond optimally to these two
groups of drugs.
Bothclassesofdrugsexertabeneﬁcial
effect on glycemic control, irrespective of
the type of background oral agents, and
both complement the action of met-
formin,TZD,andsulfonylureas.Bothdis-
play beneﬁcial effects on weight
compared with other oral antidiabetic
drugs (except DPP-4 inhibitors versus
metformin), however, more pronounced
fortheGLP-1receptoragonists(1,20,43).
Lastly, both are rarely, if ever, associated
with severe hypoglycemia if not used in
combination with sulfonylurea. The use
of DPP-4 inhibitors is simple: once- or
twice-daily oral administration. Ex-
enatide has to be injected twice daily and
is associated with relatively high rates of
nausea and vomiting initially.
TheGLP-1receptoragonistsmaybe
particularly effective in overweight pa-
tients who want to lose weight and in
overweight patients who are uncon-
trolled with oral agents, and who do
not want to start insulin treatment be-
cause of the risk of weight gain and fear,
or high risk, of hypoglycemia. The
GLP-1 receptor agonists may, in addi-
tion, have some indications in patients
with type 2 diabetes who are receiving
insulin therapy (49), either replacing it
or in addition to insulin. Experience,
however, is limited. When added to in-
sulin treatment in a 24-week study,
vildagliptin reduced A1C by 0.5% com-
pared with 0.2% in the placebo-treated
group (50).
In conclusion, incretin-based ther-
apy is a useful addition to the existing
antidiabetic drugs. Both classes of drug
can,inprinciple,successfullybeusedin
drug-naïve patients, but the ofﬁcial in-
dications are patients are being treated
with one or more oral antidiabetic
agent. Whether the patients will choose
treatment with a DPP-4 inhibitor or ex-
enatide will depend on the desire for
weight loss versus treatment with a tab-
let to avoid injection therapy. At
present, the GLP-1 receptor agonist to
be administered once daily, i.e., lira-
glutide, or once weekly, i.e., exenatide,
are in clinical development (15,31).
Incretin mimetics and DPP-4
inhibitors are so different that well-
deﬁned patient populations can be
identiﬁed for whom to use either
incretin mimetics or DPP-4
inhibitors (by A.G.)
There are distinct differences between
incretinmimeticsandDPP-4inhibitors,
ranging from their mode of administra-
tion to their effects on body weight.
These differences will inevitably lead to
a differentiation of patient groups in
whom one treatment is favored over the
other.
The ﬁve key differences are as fol-
lows: 1) GLP-1 receptor agonists are ad-
ministered via subcutaneous injection,
whereas DPP-4 inhibitors are delivered
as oral tablets; 2) GLP-1 receptor ago-
nists are probably more effective than
DPP-4 inhibitors at reducing A1C; 3)
GLP-1 receptor agonists show a more
prominent -cell preservation/improve-
menteffect than has been observed with
DPP-4 inhibitors; 4) GLP-1 receptor
agonists cause signiﬁcant weight loss,
especially in very obese patients, whereas
DPP-4 inhibitors do not induce weight
loss; and 5) GLP-1R agonists have a pos-
itive effect on systolic blood pressure,
which has not been shown by DPP-4
inhibitors.
It is simple to envisage the effect of
theﬁrstdisparity.BecauseGLP-1recep-
tor agonists are administered via subcu-
taneous injection, and DPP-4 inhibitors
are delivered as oral tablets, initiating
DPP-4 inhibitor therapy does not repre-
sent any major change in practice from
metformin/oral antidiabetic agent ther-
apy.Asaresult,DPP-4inhibitorswillbe
used earlier in the treatment algorithm
than GLP-1 receptor agonists, regard-
less of any pharmacologic similarities
the drugs may have. Indeed, their oral
administration indicates that DPP-4 in-
hibitors are likely to replace existing
oral antidiabetic agents, whereas deliv-
ery via subcutaneous injection may
Nauck and Associates
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petitors for insulin treatment. Thus, pa-
tientgroupsforwhomDDP-4inhibitors
are likely to be preferred are those who
formerly would have added an oral an-
tidiabetic agent to their regimen and,
for GLP-1 receptor agonists, those who
formerly would have initiated insulin
treatment.
Both the second and third differ-
ences (GLP-1 receptor agonists are
more effective in reducing A1C and
show a -cell preservation/improve-
ment effect) also suggest that GLP-1 re-
ceptor agonists will be used later in the
course of the disease, as insulin typi-
cally is. This is because it is usually in
patients several years after diagnosis,
when decline of incretin system func-
tion is more advanced, that both larger
decreases in A1C are necessary, and
non-insulin therapies requiring some
residual -cell function are less
effective.
The fourth key variation (i.e.,
GLP-1 receptor agonists, but not DPP-4
inhibitors,causesigniﬁcantweightloss)
clearly makes them the treatment of
choice for a large group of diabetic pa-
tients who are prominently obese.
When viewed alongside the reduction
ofsystolicbloodpressureobservedwith
GLP-1 receptor agonists but not with
DPP-4 inhibitors, it is possible to sug-
gestthatGLP-1receptoragonistswillbe
the preferred treatment in type 2 dia-
beticpatientswithBMI30kg/m
2,and
perhapsevenreplaceseveraldrugs(e.g.,
anti-obesity drugs, anti-hypertensive
drugs), despite the requirement for sub-
cutaneous administration. Therefore,
whereas very obese patients may signif-
icantly beneﬁt from GLP-1 receptor ag-
onist therapy, type 2 diabetic patients
with lower BMI may be directed toward
DPP-4 inhibitors as an easier/simpler
regimen.
These considerations, which sug-
gest that GLP-1 receptor agonists may
ﬁnd themselves classiﬁed as a third-line
alternative to insulin, should be viewed
against evidence that earlier initiation
may lead to clinical beneﬁts (51). A
drug class that does not carry the risk of
hypoglycemic episodes, or the weight
gain as associated with insulin, and can
be administered once daily indepen-
dent of meals should not be grouped as
something like a “new insulin” based on
its mode of administration.
Incretin mimetics and DPP-4
inhibitors should be incorporated in
treatment algorithms to be
published as guidelines for
treatment of type 2 diabetes
IncretinmimeticsandDPP-4inhibitors
will be an option aside from ﬁrst-line
treatmentrecommendationstobeused
in occasional patients (by B.G.). The
American Diabetes Association and the
European Association for the Study of Di-
abetes have published a joint treatment
recommendation with an algorithm for
the stepwise escalation of therapeutic
stepsinthecourseoftype2diabetes(52).
Based on evidence from clinical studies
and on available cost-effectiveness data,
exenatide, DPP-4 inhibitors, and other
novel compounds were not included in
this algorithm because of their generally
still limited clinical data and/or relative
expense. Considering the epidemiologi-
cal development of type 2 diabetes and
the ﬁnancial burden on the different
health care systems, it seems prudent to
use cost-effective nonpharmacological
and cheap pharmacological interventions
in type 2 diabetes. Conversely, the estab-
lishedtherapieshavetheirlimitationsand
draw-backs (53). From this perspective,
the novel therapeutic options could be
usedinoccasionalpatients,i.e.,DPP-4in-
hibitors as oral therapy when hypoglyce-
miapreventionisimportant(e.g.,patients
withhypoglycemiaunawareness,patients
operating motor vehicles or heavy ma-
chines, geriatric patients) or when further
weight gain is undesirable due to con-
comitant complications of obesity and a
strongwishtoloseweight.Thelattercon-
ditionwouldfavorincretinmimeticsover
DPP-4 inhibitors, because weight loss is
associated with this treatment option. As
long as more long-term data, studies with
hard clinical end points, and cost-
effectivenessdatafromstudieswithincre-
tin-based therapies are lacking, it is
difﬁcult to judge which patient popula-
tions comprise the pertinent characteris-
tics that will proﬁt most from such a
therapy compared with standard treat-
ment. This is especially valid for patients
who failed oral treatment with two agents
and are already on multiple oral com-
pounds, or on insulin therapy. Con-
versely, the still limited study results
allow the use of incretin mimetics and
DPP-4 inhibitors in occasional patients
who, from current knowledge, will most
likelybeneﬁtfromthistherapy.Thesepa-
tients should be followed up closely to
gainmoredataonthesetreatmentoptions
in an everyday clinical setting apart from
controlled clinical trials. Only in this way
and in conjunction with further study
data, patient characteristics, and treat-
ment situations will we ascertain better
deﬁnitions that may ﬁnally lead to novel
guidelines.
Incretin mimetics and DPP-4 inhibitors
will ﬁnd a place/be included as standard
treatment in certain well-characterized
patients and/or situations (by T.V.). De-
spitetherangeoforalagentstargetingdif-
ferentfacetsofdiabetes(metformin,TZD,
insulin sensitizers, sulfonylureas), avail-
able treatment paradigms are unsatisfac-
tory,withmanypatientsfailingtoachieve
adequate glycemic control, even when
multidrug approaches are used. Patients
remain inadequately treated, because ex-
isting therapies have a number of short-
comings, including inadequate efﬁcacy in
glucose lowering, limited durability of
glycemic response, inconvenient dosing
regimens, and safety and tolerability is-
sues. The latter include hypoglycemia
(sulfonylureas,meglitinides,andinsulin),
body weight gain (sulfonylureas, meg-
litinides, insulin, and TZDs), and gas-
trointestinal intolerance (metformin
and -glucosidase inhibitors). There is,
therefore, a need for new and more ef-
ﬁcacious agents, targeted not only at
treatment, but also at prevention of the
disease, its progression, and its associ-
ated complications.
As the treatment efﬁcacy of mimetics
and enhancers have been ﬁrmly estab-
lished in respect to lowering A1C, and
improved -cell function during treat-
ment, these treatment modalities are ex-
pected to ﬁnd a place/be incorporated as
standard treatments (40) and to be in-
cluded in the recommendations for the
treatment of type 2 diabetes within com-
ingyears.Todate,themainpartofclinical
trials with the new treatment modalities
have been conducted in patients with
new-onset type 2 diabetes or patients be-
ing treated with one or two antidiabetic
drugs (1). Therefore, studies including
patients with pre-diabetes and patients in
the later stages of diabetes, e.g., when
treated with insulin/on insulin therapy,
areimportanttoevaluatetheapplicability
indifferentstagesofdiabetes.Inaddition,
long-term clinical studies with a broader
rangeofclinicalendpoints(includingtri-
als with cardiovascular end points) are
warranted to reveal the true beneﬁts of
enhancing incretin actions and enable a
more effective treatment of a broader
spectrum of patients.
Incretin-based therapies
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M.A.N.)— As may be expected for
relatively novel classes of antidiabetic
agents, incretin mimetics and DPP-4 in-
hibitors receive a lot of attention be-
cause they display properties that make
them attractive antidiabetic agents and,
on ﬁrst sight, present advantages over
existingolderagents,namelyabsenceof
any risk of hypoglycemia and weight
loss/weight neutrality, respectively. On
the other hand, based on phase 3 clini-
cal trial data and some experience
gained after approval, many open
questions remain, and the discussion
regarding their therapeutic value, and
concerning the appropriate place
within treatment algorithms for type 2
diabetic patients, will have to continue
in the coming years.
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